ImmunityBio secured exclusive U.S. development and supply rights for the Tokyo-172 strain of BCG, an investigational bladder cancer therapy not yet FDA-approved. This follows positive Phase 3 trial results showing Tokyo-172 BCG is as effective as the current TICE BCG in treating high-grade non-muscle invasive bladder cancer. ImmunityBio plans to engage with the FDA to address the long-standing BCG shortage in the U.S. Additionally, the company expanded its patent protection for its ANKTIVA plus BCG treatment platform, strengthening its bladder cancer franchise through at least 2035.
SharonAI Holdings reported a first-quarter EPS loss of $1.43, slightly worse than last year's $1.34 loss, with revenue declining to $294,014 from $325,092. Despite this, the company highlighted strong demand for its AI cloud services and announced an...
Baidu reported strong Q1 2026 earnings, with EPS of $1.75 surpassing analyst expectations of $1.67 and revenue of $4.65 billion beating estimates of $4.54 billion. The company's rapid growth in AI-powered cloud services now accounts for over half of ...
Arbor Biotechnologies appointed Mathew Pletcher, Ph.D., as its new Chief Scientific Officer, succeeding John Murphy who is retiring. Dr. Pletcher brings nearly 20 years of experience in gene therapy and rare diseases, having held leadership roles at ...
GetDandy has introduced an autonomous AI workforce platform that provides local businesses with enterprise-level tools for communications, marketing, and reputation management. The platform handles customer interactions across multiple channels like ...
CBAK Energy Technology reported a 99.3% year-over-year revenue increase to $69.62 million in Q1 2026, fueled by expanded production capacity and strong demand in light electric vehicles and battery raw materials. The battery segment grew 84.3%, with ...
